Gregory I. Frost, Ph.D., was the CEO of Halozyme Therapeutics, a biotechnology company he co-founded in 1999. Dr. Frost took the helm as CEO on December 2, 2010, after serving in other executive roles within the company, including Vice President...

Gregory I. Frost, Ph.D., was the CEO of Halozyme Therapeutics, a biotechnology company he co-founded in 1999. Dr. Frost took the helm as CEO on December 2, 2010, after serving in other executive roles within the company, including Vice President and Chief Scientific Officer. Under his leadership, Halozyme focused on developing and advancing multiple drug products, aiming to enhance treatment for various diseases. His tenure saw significant resource allocation towards research and development, promoting strategic partnerships to expand the company’s reach. A notable point in Dr. Frost's career was his departure from Halozyme in early 2014, which marked a transition in company leadership. During his time, he was involved in plans to optimize executive compensation, tying it directly to company performance metrics, which indicates a clear focus on aligning executive goals with shareholder interests. One interesting moment was the considerable insider trading fluctuations in Halozyme’s stock price during his leadership. Dr. Frost's experience and focus on performance shaped the company's strategies during critical years in the market.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Halozyme Therapeutics CEOs

H

Gregory I. Frost, Ph.D.

Founder and Ex-CEO of Halozyme Therapeutics

Education

Not specified

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

January 1, 1971 - 54 years ago

CEO of Halozyme Therapeutics for

3 years 1 month (Dec 2010 - Jan 2014)

Previous Experience

Co-founder of Halozyme Therapeutics, Inc.

Rivals

Competitors/colleagues of Gregory I. Frost, Ph.D.

Holdings

See how much did Gregory I. Frost, Ph.D. make over time.

Throughout his time at Halozyme, Gregory I. Frost held significant stock options, with his holdings experiencing substantial fluctuations. In December 2019, it was reported that his trades reached a value of around $68.57 million. His holdings peaked in early 2021,...

Throughout his time at Halozyme, Gregory I. Frost held significant stock options, with his holdings experiencing substantial fluctuations. In December 2019, it was reported that his trades reached a value of around $68.57 million. His holdings peaked in early 2021, reaching an impressive $169.31 million, reflecting investor confidence during the company's growth phases. However, by early 2024, the value had decreased to approximately $128.60 million, showing the volatility inherent in the biotech sector. This dynamic illustrates both his investment acumen and the challenges faced by the industry, as stock values can shift dramatically based on product developments and market conditions.

Insider Trading

See recent insider trades of Gregory I. Frost, Ph.D..

HALO

$11.00K

HALO at $5.50/share

Aug 13, 2012

Purchase

HALO

$35.04K

HALO at $5.84/share

Aug 9, 2011

Purchase

Compensation History

See how much did Gregory I. Frost, Ph.D. make over time.

In 2014, as the CEO of Halozyme Therapeutics, Gregory I. Frost received a total compensation package of over $10 million. This included a salary of $593,391 and a performance-based bonus of $1 million, designed to replace a bonus he missed from his previous employer. His total compensation was heavily weighted towards options, indicating a compensation strategy focused on aligning his financial interests with the company’s performance. In prior years, from 2011 to 2013, his compensation varied significantly, indicating the company’s performance directly influenced his earnings. For instance, in 2013, his total compensation was around $1.5 million, showcasing a compensation structure that changed with the company’s fortunes. This method of compensation is common in the biotech sector, where aligning executive pay with company performance can drive better operational results.

Year

2014

Total Compensation

$1.82M

Salary

$593.39K

Board Justification

The compensation philosophy is designed to align the interests of executives with those of stockholders, focusing on performance-based metrics and competitive compensation to attract and retain top talent.

Bonus

$1.00M

Board Justification

This bonus was intended to replace an equivalent bonus that Dr. Frost would have earned from his former employer.

Other

$227.88K

Board Justification

Includes reimbursement of relocation expenses and contributions to the 401(k) plan.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock awards vested in 2014 as the focus was on cash compensation and bonuses.

Performance Metrics

Performance metrics include revenue growth, operational efficiency, and strategic partnerships.

Other Halozyme Therapeutics CEOs

Here are other CEOs of Halozyme Therapeutics

Dr. Helen I. Torley, M.B., Ch.B, M.R.C.P.

CEO of Halozyme Therapeutics

January 2014 - Present